NCT03886831: A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

NCT03886831
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with uncontrolled CNS metastases; Patients with rior treatment with chimeric antigen receptor T cells (CAR-T cells)
https://ClinicalTrials.gov/show/NCT03886831

Comments are closed.

Up ↑